Literature DB >> 32659371

Dapagliflozin improves behavioral dysfunction of Huntington's disease in rats via inhibiting apoptosis-related glycolysis.

Ayman E El-Sahar1, Alyasaa A Rastanawi2, Muhammed F El-Yamany3, Muhammed A Saad4.   

Abstract

AIMS: Huntington's disease is a rare neurodegenerative disorder which is associated with defected glucose metabolism with consequent behavioral disturbance including memory and locomotion. 3-nitropropionic acid (3-NP) can cause, in high single dose, an acute striatal injury/Huntington's disease. Dapagliflozin, which is one of the longest duration of action of SGLTIs family, may be able to diminish that injury and its resultant behavioral disturbances.
MATERIAL AND METHODS: Forty rats were divided into four groups (n = 10 in each group): normal control group (CTRL), dapagliflozin (CTRL + DAPA) group, 3-nitropropionic acid (3-NP) group, and dapagliflozin plus 3-nitropropionic acid (DAPA + 3-NP) group. Behavioral tests (beam walking test, hanging wire test, limb withdrawal test, Y-maze spontaneous alteration, elevated plus maze) were performed with evaluating neurological scoring. In striatum, neurotransmitters (glutamate, aspartate, GABA, ACh and AChE activity) were measured. In addition, apoptosis and glycolysis markers (NF-κB, Cyt-c, lactate, HK-II activity, P53, calpain, PEA15 and TIGAR) were determined. Inflammation (IL-1β, IL-6, IL-8 and TNF-α) and autophagy (beclin-1, LC3 and DRAM) indicators were measured. Additionally, histopathological screening was conducted. KEY
FINDINGS: 3-Nitropropionic acid had the ability to perturb the neurotransmission which was reflected in impaired behavioral outcome. All of glycolysis, apoptosis and inflammation markers were elevated after 3-NP acute intoxication but autophagy parameters, except DRAM, were reduced. However, DAPA markedly reversed the abovementioned parameters. SIGNIFICANCE: Dapagliflozin demonstrated anti-glycolytic, anti-apoptotic, anti-inflammatory and autophagic effects on 3-NP-damaged striatal cells and promoted the behavioral outcome.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3-Nitropropionic acid; Dapagliflozin; Huntington's disease; Locomotion; Memory

Mesh:

Substances:

Year:  2020        PMID: 32659371     DOI: 10.1016/j.lfs.2020.118076

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Anti-Huntington's Effect of Butin in 3-Nitropropionic Acid-Treated Rats: Possible Mechanism of Action.

Authors:  Sultan Alshehri; Fahad A Al-Abbasi; Mohammed M Ghoneim; Syed Sarim Imam; Muhammad Afzal; Khalid Saad Alharbi; Muhammad Shahid Nadeem; Nadeem Sayyed; Imran Kazmi
Journal:  Neurotox Res       Date:  2022-01-04       Impact factor: 3.911

2.  Dapagliflozin as an autophagic enhancer via LKB1/AMPK/SIRT1 pathway in ovariectomized/D-galactose Alzheimer's rat model.

Authors:  Weam W Ibrahim; Ahmed S Kamel; Ahmed Wahid; Noha F Abdelkader
Journal:  Inflammopharmacology       Date:  2022-04-01       Impact factor: 4.473

3.  Berberine Ameliorate Haloperidol and 3-Nitropropionic Acid-Induced Neurotoxicity in Rats.

Authors:  Abdul Kadir; Jasdeep Singh; Vikrant Rahi; Puneet Kumar
Journal:  Neurochem Res       Date:  2022-07-25       Impact factor: 4.414

4.  Crosstalk Among NLRP3 Inflammasome, ETBR Signaling, and miRNAs in Stress-Induced Depression-Like Behavior: a Modulatory Role for SGLT2 Inhibitors.

Authors:  Radwa N Muhammad; Lamiaa A Ahmed; Rania M Abdul Salam; Kawkab A Ahmed; Amina S Attia
Journal:  Neurotherapeutics       Date:  2021-10-18       Impact factor: 6.088

Review 5.  Regulated cell death: discovery, features and implications for neurodegenerative diseases.

Authors:  Juntao Cui; Suhan Zhao; Yinghui Li; Danyang Zhang; Bingjing Wang; Junxia Xie; Jun Wang
Journal:  Cell Commun Signal       Date:  2021-12-18       Impact factor: 5.712

Review 6.  Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review.

Authors:  Thahesh Tharmaraja; Jamie S Y Ho; Ching-Hui Sia; Nicole-Ann Lim; Yao Feng Chong; Amanda Y L Lim; Rahul R Rathakrishnan; Leonard L L Yeo; Vijay K Sharma; Benjamin Y Q Tan
Journal:  Ther Adv Chronic Dis       Date:  2022-04-11       Impact factor: 5.091

Review 7.  The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors.

Authors:  Meiyuan Dong; Song Wen; Ligang Zhou
Journal:  Diabetes Metab Syndr Obes       Date:  2022-08-22       Impact factor: 3.249

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.